Parkinson’s disease, antiparkinson medicines, and driving

References

• Rana AQ, Ahmed US, Chaudry ZM, et al. Parkinson’s disease: a review of non-motor symptoms. Expert Rev Neurother. 2015;15:549–562.
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease. CNS Drugs. 2008;22:563–586.
   PubMed Web of Science ®Google Scholar
• Crizzle AM, Classen S, Uc EY. Parkinson disease and driving: an evidence-based review. Neurology. 2012;79:2067–2074.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Pal G. Initial management of Parkinson’s disease. BMJ. 2014;349:g6258.
   Google Scholar
• LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86(14 Suppl 1):S3–S12.
   PubMed Web of Science ®Google Scholar
• Avanzi M, Baratti M, Cabrini S, et al. The thrill of reckless driving in patients with Parkinson’s disease: an additional behavioural phenomenon in dopamine dysregulation syndrome? Parkinsonism Relat Disord. 2008;14:257–258.
   PubMed Web of Science ®Google Scholar
• Newman NJ. Driving with Parkinson’s disease: more than meets the eye. Ann Neurol. 2006;60:387–388.
   PubMed Web of Science ®Google Scholar
• Schrag A. Driving in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:159.
   PubMed Web of Science ®Google Scholar
• Uc EY, Rizzo M. Driving and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2008;8:377–383.
   PubMed Web of Science ®Google Scholar
• Wood JM, Worringham C, Kerr G, et al. Quantitative assessment of driving performance in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:176–180. Erratum in: J Neurol Neurosurg Psychiatry 2005; 76: 458.
   PubMed Web of Science ®Google Scholar
• Uc EY, Rizzo M, Anderson SW, et al. Impaired visual search in drivers with Parkinson’s disease. Ann Neurol. 2006;60:407–413.
   PubMed Web of Science ®Google Scholar
• Dubinsky RM1, Gray C, Husted D, et al. Driving in Parkinson’s disease. Neurology. 1991;41:517–520.
   PubMed Web of Science ®Google Scholar
• Uc EY, Rizzo M, Johnson AM, et al. Real-life driving outcomes in Parkinson disease. Neurology. 2011;76:1894–1902.
   PubMed Web of Science ®Google Scholar
• Orriols L, Avalos-Fernandez M, Moore N, et al. Long-term chronic diseases and crash responsibility: a record linkage study. Accid Anal Prev. 2014;71:137–143.
   PubMed Web of Science ®Google Scholar
• Meindorfner C, Körner Y, Möller JC, et al. Driving in Parkinson’s disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20:832–842.
   PubMed Web of Science ®Google Scholar
• Unsworth CA, Baker A. Driver rehabilitation: a systematic review of the types and effectiveness of interventions used by occupational therapists to improve on-road fitness-to-drive. Accid Anal Prev. 2014;71:106–114.
   PubMed Web of Science ®Google Scholar
• Austroads. Assessing fitness to drive for commercial and private vehicle drivers medical standards for licensing and clinical management guidelines. March 2012 as amended up to 30 June 2014. Sydney: Austroads, 2014. Austroads Publication Number: AP-G56-13. https://www.onlinepublications.austroads.com.au/downloads/AP-G56-13
   Google Scholar
• Dobbs BM. Medical conditions and driving: a review of the literature (1960-2000). Washington (DC): US Department of Transport; 2005. [cited 2016 Apr 11]. Available from: www.nhtsa.gov/people/injury/research/MedicalConditions_Driving.pdf.
   Google Scholar
• European Commission. Council directive 91/439/EEC of 29 July 1991 on driving licenses. Official Journal. 1991;L 237:0001–0024.
   Google Scholar
• European Commission. Mobility and transport. Road safety. Fitness to drive. [ cited 2016 Apr 11]. Available from: http://ec.europa.eu/transport/road_safety/topics/behaviour/fitness_to_drive/index_en.htm.
   Google Scholar
• Ranchet M, Tant M, Akinwuntan AE, et al. Comorbidity in drivers with Parkinson’s disease. J Am Geriatr Soc. 2016;64:342–346.
   PubMed Web of Science ®Google Scholar
• Klimkeit EI, Bradshaw JL, Charlton J, et al. Driving ability in Parkinson’s disease: current status of research. Neurosci Biobehav Rev. 2009;33:223–231.
   PubMed Web of Science ®Google Scholar
• Gómez-Talegón MT, Fierro I, Vicondoa A, et al. [Fitness-to-drive assessment in drivers with neurological and neuromuscular disorders at the driving test centres]. Rev Neurol. 2007;45:526–531.
   PubMed Web of Science ®Google Scholar
• Lachenmayer L. Parkinson’s disease and the ability to drive. J Neurol. 2000;247(Suppl S4):IV28–30.
   Google Scholar
• DRUID. Final report: work performed, main results and recommendations. Revisión 2.0. Cologne: BAST; 2012. [cited 2016 Apr 11]. Available at: http://www.druid-project.eu/Druid/EN/Dissemination/downloads_and_links/Final_Report.html?nn=613800DRUID Final Report
   Google Scholar
• Schulze H, Schumacher M, Urmeew R, et al. Driving under the influence of drugs, alcohol and medicines in Europe — findings from the DRUID project. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2012. http://www.emcdda.europa.eu/attachements.cfm/att_192773_EN_TDXA12006ENN.pdf.
   Google Scholar
• Ravera S, Monteiro SP, De Gier JJ, et al. the DRUID Project WP4 Partners. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012;74:920–931.
   PubMed Web of Science ®Google Scholar
• De Gier JJ, Alvarez FJ, Mercier-Guyon C, et al. Prescribing and dispensing guidelines for medicinal drugs affecting driving performance. In: Verster JC, Pandi-Perumal SR, Ramaekers JG, et al., editors. Drugs, driving and traffic safety. Basel: Birkaeuser Verlag AG; 2009. p. 121–134.
   Google Scholar
• Alvarez FJ, Del Río MC. Medicinal drugs and driving: from research to clinical practice. Trends Pharmacol Sci. 2002;23:441–443.
   PubMed Web of Science ®Google Scholar
• Ministère de la Santé et des Solidarités. Arrêté du 18 Juillet 2005 pris pour l´application de l´article R.5121-139 du code de la santé publique et relative à l´opposition d´un pictogramme sur le conditionnement extérieur de certain médicaments et produits. 2005. JORF n°178 du 2 août 2005. p. 12595 (SAN/P0522726A).
   Google Scholar
• Real Decreto 1345/2007, de 11 de octobre, por el que se regula el procedimiento de autorización, registro y condiciones de dispensación de los medicamentos de uso humano fabricados industrialmente. BOE de 7 de Noviembre de 2007. p. 45652–45698.
   Google Scholar
• Fierro I, Gómez-Talegón T, Alvarez FJ. The Spanish pictogram on medicines and driving: the population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev. 2013;50:1056–1061.
   PubMed Web of Science ®Google Scholar
• Contra-indicatie Verkeersdeelname (in Dutch) [Contra-indication “participation in traffic”]. [ cited 2016 Apr 11]. Available from: www.geneesmiddeleninhetverkeer.nl.
   Google Scholar
• ICADTS Working group on Prescribing and Dispensing Guidelines for Medicinal Drugs Affecting Driving Performance. Categorization system for medicinal drugs affecting driving performance. International Council on Alcohol, Drugs & Traffic Safety, 2007. [cited 2016 Apr 11]. Available from: http://www.icadts.nl/medicinal.html.
   Google Scholar
• European Council Directive 83/570/EEC of 26 October 1983. Council Directive 83/570/EEC of 26 October 1983 amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. [ cited 2016 Apr 11]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A31983L0570.
   Google Scholar
• Gómez-Talegón T, Fierro I, Del Río MC, et al. Establishment of framework for classification/categorization and labelling of medicinal drugs and driving. Deliverable 4.3.1, 2011. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. [ cited 2016 Apr 11]. Available from: http://www.druid-project.eu/.
   Google Scholar
• Selegiline. Summary of product characteristics. [cited 2016 Apr 11]. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1454044447123.pdf.
   Google Scholar
• Heklany® (Rasagiline). Summary of product characteristics. [ cited 2016 Apr 11]. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1450415494231.pdf.
   Google Scholar
• Müller T. Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Expert Rev Neurother. 2013;13:969–977.
   PubMed Web of Science ®Google Scholar
• Xadago® (Safinamida). Summary of product characteristics. European Medicines Agency. [cited 2016 Apr 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002396/WC500184965.pdf.
   Google Scholar
• Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease. Expert Rev Neurother. 2016;16:245–258.
   PubMed Web of Science ®Google Scholar
• Dungo R, Deeks ED. Istradefylline: first global approval. Drugs. 2013;73:875–882.
   PubMed Web of Science ®Google Scholar
• Müller T. The safety of istradefylline for the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2015;14:769–775.
   PubMed Web of Science ®Google Scholar
• Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology. 2005;64(12 Suppl 3):S12–S20.
   Google Scholar
• Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson’s disease: what is currently known? CNS Drugs. 2003;17:593–600.
   PubMed Web of Science ®Google Scholar
• Comella CL. Daytime sleepiness, agonist therapy, and driving in Parkinson disease. JAMA. 2002;287:509–511.
   PubMed Web of Science ®Google Scholar
• Uitti RJ, Wszolek ZK. Dopamine agonists, sleep disorders, and driving in Parkinson’s disease. Adv Neurol. 2003;91:343–349.
   PubMedGoogle Scholar
• Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287:455–463.
   PubMed Web of Science ®Google Scholar
• Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ. 2002;324:1483–1487.
   PubMed Web of Science ®Google Scholar
• Möller JC, Stiasny K, Cassel W, et al. [“Sleep attacks” in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?]. Nervenarzt. 2000;71:670–676.
   PubMed Web of Science ®Google Scholar
• Chou KL. Adverse events from the treatment of Parkinson’s disease. Neurol Clin. 2008;26(3 Suppl):S65–S83.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 2007;21:677–692.
   PubMed Web of Science ®Google Scholar
• Sweetman SC, editor. Dopaminergics. In: Martindale. The complete drug reference. 34th ed. London: Pharmaceutical Press; 2005. p. 1196–1216.
   Google Scholar
• Simonson W, Hauser RA, Schapira AH. Role of the pharmacist in the effective management of wearing-off in Parkinson’s disease. Ann Pharmacother. 2007;41:1842–1849.
   PubMed Web of Science ®Google Scholar
• Emre M, Ford PJ, Bilgiç B, et al. Cognitive impairment and dementia in Parkinson’s disease: practical issues and management. Mov Disord. 2014;29:663–672.
   PubMed Web of Science ®Google Scholar
• Hussl A, Seppi K, Poewe W. Nonmotor symptoms in Parkinson’s disease. Expert Rev Neurother. 2013;13:581–583.
   PubMed Web of Science ®Google Scholar
• Coakeley S, Martens KE, Almeida QJ. Management of anxiety and motor symptoms in Parkinson’s disease. Expert Rev Neurother. 2014;14:937–946.
   PubMed Web of Science ®Google Scholar
• Classen S. Consensus statements on driving in people with Parkinson’s disease. Occup Ther Health Care. 2014;28:140–147.
   PubMedGoogle Scholar
• Dickerson AE. Screening and assessment tools for determining fitness to drive: a review of the literature for the pathways project. Occup Ther Health Care. 2014;28:82–121.
   PubMedGoogle Scholar
• American Medical Association, National Highway Traffic Safety Administration. Physician’s guide to assessing counseling older drivers. [ cited 2016 Apr 11]. Available from: http://www.nhtsa.gov/people/injury/olddrive/OlderDriversBook/pages/Contents.html.
   Google Scholar
• Rizzo M. Impaired driving from medical conditions: a 70-year-old man trying to decide if he should continue driving. JAMA. 2011;305:1018–1026.
   PubMed Web of Science ®Google Scholar
• Caruso G, Dawson J, DeLuca J, et al. Opinions of expert panel: Parkinson’s disease, multiple sclerosis, and commercial motor vehicle driver safety. Federal Motor Carrier Safety Administration, 2009. [cited 2016 Apr 11]. Available from: https://www.fmcsa.dot.gov/sites/fmcsa.dot.gov/files/docs/PD_MS_MEP_Opinions_09212009.pdf.
   Google Scholar
• National Highway Traffic Safety Administration (NHTSA). Driver Fitness Working Group of the American Association of Motor Vehicle Administrators (AAMVA). Driver fitness medical guidelines. 2009. [cited 2016 Apr 11]. Available from: http://ntl.bts.gov/lib/31000/31100/31148/6061_MedicalReviewGuide_10-1_v2a.pdf.
   Google Scholar
• Espay AJ, Bonato P, Nahab FB, et al., Movement Disorders Society Task Force on Technology. Technology in Parkinson’s disease: challenges and opportunities. Mov Disord. 2016. Version of Record online: 29 april 2016. doi:10.1002/mds.26642.
   Google Scholar
• Orriols L, Salmi L-R, Philip P, et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf. 2009;18:647–658.
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Martinez-Martin P. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview. Expert Rev Neurother. 2013;13:1329–1342.
   PubMed Web of Science ®Google Scholar
• Freitas ME, Fox SH. Nondopaminergic treatments for Parkinson’s disease: current and future prospects. Neurodegener Dis Manag. 2016 May 27;6:249–268.
   PubMedGoogle Scholar
• Vorovenci RJ, Antonini A. The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease. Expert Rev Neurother. 2015;15:1383–1390.
   PubMed Web of Science ®Google Scholar
• Ramirez-Zamora A, Molho E. Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions. Expert Rev Neurother. 2014;14:93–103.
   PubMed Web of Science ®Google Scholar
• Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson’s disease. Expert Rev Neurother. 2014;14:143–149.
   PubMed Web of Science ®Google Scholar
• Akbar U, Friedman JH. Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease. Expert Rev Neurother. 2015;15:1053–1065.
   PubMed Web of Science ®Google Scholar
• Li K, Reichmann H, Ziemssen T. Recognition and treatment of autonomic disturbances in Parkinson’s disease. Expert Rev Neurother. 2015;15:1189–1203.
   PubMed Web of Science ®Google Scholar